Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTUS hypertension and optional lipid-lowering trial after ischaemic stroke or TIA
ACTRN12624001279516Phase 3Recruiting
- Sponsor
- The George Institute for Global Health
- Start
- Oct 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of telmisartan, amlodipine, indapamide, rosuvastatin, ezetimibe and 1 more in hypertension (HTN) and hypercholesterolemia (4 arms), sponsored by The George Institute for Global Health. Primary endpoint: Proportion achieving blood pressure control. Started Oct 2025; status: recruiting.
02
Drugs
telmisartanamlodipineindapamiderosuvastatinezetimibe
03
Conditions
hypertension (HTN)hypercholesterolemia
Beyond the preview
Go deeper on ACTRN12624001279516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001279516.